0001559053 2025-01-01 2025-12-31 0001559053 2024-01-01 2024-12-31 0001559053 2023-01-01 2023-12-31 0001559053 2022-01-01 2022-12-31 0001559053 2021-01-01 2021-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2025-01-01 2025-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2023-01-01 2023-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2022-01-01 2022-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2021-01-01 2021-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2025-01-01 2025-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2023-01-01 2023-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2022-01-01 2022-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2021-01-01 2021-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001559053 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001559053 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001559053 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001559053 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001559053 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001559053 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001559053 1 2025-01-01 2025-12-31 0001559053 2 2025-01-01 2025-12-31 0001559053 3 2025-01-01 2025-12-31 iso4217:USD DEF 14A 0001559053 false PROTHENA CORPORATION PUBLIC LIMITED COMPANY true <div style="text-align:justify"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth information regarding the Company’s performance and the “compensation actually paid” to our named executive officers, as calculated in accordance with SEC disclosure rules:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="6" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Value of Initial Fixed $100</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Investment Based on:</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Year </span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Summary</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Compensation</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Table Total</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">for PEO</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Compensation</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Actually Paid</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">to PEO</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Summary</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Compensation</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Table Total for</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Non-PEO</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Named</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Executive</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Officers</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Compensation</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Actually Paid</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">to Non-PEO</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Named</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Executive</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Officers</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shareholder</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Return</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Peer Group</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shareholder</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Return</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Net Income</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Loss)</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($ in</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">thousands)</span></div></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Company</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Selected</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Measure</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,896,045 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,866,614 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,575,012 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,856,409 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119.92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(244,092)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,230,959 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,707,034)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,488,366 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(204,492)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115.32 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90.58 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122,310)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,043,826 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,218,100)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,644,678 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,225,533)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302.58 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91.84 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(147,028)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,736,055 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,400,610 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,696,607 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,104,503 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501.67 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.53 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(116,949)</span></td><td style="background-color:#ffffff;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,918,363 </span></td><td style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,144,072 </span></td><td style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,852,428 </span></td><td style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,625,320 </span></td><td style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">411.32 </span></td><td style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.37 </span></td><td style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66,975 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td></tr></table></div> 5896045 2866614 2575012 1856409 79.52 119.92 -244092000 7230959 -1707034 2488366 -204492 115.32 90.58 -122310000 7043826 -3218100 2644678 -1225533 302.58 91.84 -147028000 6736055 7400610 2696607 4104503 501.67 88.53 -116949000 4918363 41144072 2852428 12625320 411.32 99.37 66975000 <span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">Gene G. Kinney served as the Company’s principal executive officer for the entirety of 2021, 2022, 2023, 2024, and 2025 and the Company’s other named executive officers for the applicable years were as follows:</span><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:13.24pt">2025: Tran B. Nguyen, Brandon S. Smith, Chad J. Swanson, Wagner M. Zago</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:13.24pt">2024: Carol D. Karp, Tran B. Nguyen, Brandon S. Smith, Wagner M. Zago.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:13.24pt">2021-2023: Hideki Garren, Carol D. Karp, Tran B. Nguyen, Brandon S. Smith.</span></div> Gene G. Kinney Gene G. Kinney Gene G. Kinney Gene G. Kinney Gene G. Kinney <span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">Amounts reported in this column represent (i) the total compensation reported in the Summary Compensation Table for the applicable year in the case of Dr. Kinney and (ii) the average of the total compensation reported in the Summary Compensation Table for the applicable year for the Company’s named executive officers for the applicable year other than Dr. Kinney.</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">Pursuant to rules of the SEC, the comparison assumes $100 was invested on December 31, 2020, in our ordinary shares. Historic share price performance is not necessarily indicative of future share price performance.</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">As noted in the Compensation Discussion and Analysis for 2025, the principal incentive elements in the Company’s executive compensation program were delivered in the form of annual cash bonuses and equity awards in the form of options. As is the case with many companies in the biotechnology industry, the Company’s annual incentive objectives are generally tied to the Company’s strategic and operational goals rather than financial goals. In addition, the option awards are structured as time-based awards and are not tied to the achievement of underlying performance goals. Accordingly, the Company does not have a financial metric in its program that it would have as the most important financial measure linking compensation to the Company’s financial performance, particularly as the pay versus performance table includes our TSR performance which is linked to the value of the stock options held by our named executive officers.</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">On May 19, 2020, our shareholders approved a "value-for-value" option exchange program. Pursuant to this program, we offered the option exchange in an issuer tender offer closing on February 12, 2021. Dr. Kinney, Mr. Nguyen, and Ms. Karp received replacement options in the “value-for-value” option exchange program. If those replacement options are excluded from the calculations, the compensation actually paid to Dr. Kinney in 2021 would be $29.4M (a reduction of $11.8M), and the average compensation actually paid to the Non-PEO Named Executive Officers would be $10.1M (a reduction of $2.5M).</span> <span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">Amounts reported in this column represent the compensation actually paid to Dr. Kinney as the Company’s President and Chief Executive Officer in the indicated fiscal years, based on his total compensation reported in the Summary Compensation Table for the indicated fiscal years and adjusted as shown in the table below: </span><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:0.1%"></td><td style="width:2.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="30" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PEO</span></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary Compensation Table - Total Compensation</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,896,045 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,230,959 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,043,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,736,055 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,918,363 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,771,538)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,168,827)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,039,017)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,705,925)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,900,675)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,209,603 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,251,121 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,269,118 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,228,032 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,225,521 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(925,264)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,865,913)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,418,699)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,227,286 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,810,891 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542,232)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,154,374)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,073,328)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,084,838)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,342,873 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252,901)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">=</span></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation Actually Paid</span></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,866,614</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,707,034)</span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,218,100)</span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,400,610</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,144,072</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.7pt">Represents Total Compensation as reported in the Summary Compensation Table for the indicated fiscal year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.53pt">Represents the aggregate grant date fair value of the option awards granted to Dr. Kinney during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:7.3pt">Represents the aggregate fair value as of the indicated fiscal year-end of Dr. Kinney’s outstanding and unvested option awards granted during such fiscal year, computed in accordance with the methodology used for financial reporting purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.53pt"> Represents the aggregate change in fair value during the indicated fiscal year of the outstanding and unvested option awards held by Dr. Kinney as of the last day of the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes and, for awards subject to performance-based vesting conditions, based on the probable outcome of such performance-based vesting conditions as of the last day of the fiscal year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.74pt">Represents the aggregate fair value at vesting of the option awards that were granted to Dr. Kinney and vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:8.57pt">Represents the aggregate change in fair value, measured from the prior fiscal year-end to the vesting date, of each option award held by Dr. Kinney that was granted in a prior fiscal year and which vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.53pt">Represents the aggregate fair value as of the last day of the prior fiscal year of Dr. Kinney’s option awards that were granted in a prior fiscal year and which failed to meet the applicable vesting conditions in the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div> 5896045 7230959 7043826 6736055 4918363 -4771538 -6168827 -6039017 -5705925 -3900675 3209603 2251121 3269118 12228032 23225521 -925264 -2865913 -5418699 2227286 8810891 0 0 0 0 0 -542232 -2154374 -2073328 -8084838 8342873 0 0 0 0 -252901 2866614 -1707034 -3218100 7400610 41144072 <span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">Amounts reported in this column represent the compensation actually paid to the Company’s named executive officers other than Dr. Kinney in the indicated fiscal year, based on the average total compensation for such named executive officers reported in the Summary Compensation Table for the indicated fiscal year and adjusted as shown in the table below: </span><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:0.1%"></td><td style="width:2.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="27" style="background-color:#78bfbf;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Other Named Executive Officers</span><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td><td colspan="3" style="background-color:#78bfbf;padding:0 1pt"></td><td colspan="3" style="background-color:#78bfbf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary Compensation Table - Total Compensation</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,575,012 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,488,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,644,678 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,696,607 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,852,428 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,770,538)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,707,982)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,870,147)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,940,015)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,154,308)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,479,875 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623,274 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,012,372 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,157,531 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,328,264 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269,292)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(931,629)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,233,022)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099,351 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776,040 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158,648)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(676,521)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(779,414)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,908,971)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,869,973 </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,077)</span></td><td style="border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">=</span></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation Actually Paid</span></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,856,409</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(204,492)</span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,225,533)</span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,104,503</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,625,320</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1.5pt solid #27596a;border-top:1pt solid #27596a;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.7pt">Please see footnote 1 for the named executive officers included in the average for each indicated fiscal year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.53pt">Represents the average Total Compensation as reported in the Summary Compensation Table for the reported named executive officers in the indicated fiscal year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:7.3pt">Represents the average aggregate grant date fair value of the option awards granted to the reported named executive officers during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.53pt">Represents the average aggregate fair value as of the indicated fiscal year-end of the reported named executive officers’ outstanding and unvested option awards granted during such fiscal year, computed in accordance with the methodology used for financial reporting purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.74pt">Represents the average aggregate change in fair value during the indicated fiscal year of the outstanding and unvested option awards held by the reported named executive officers as of the last day of the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:8.57pt">Represents the average aggregate fair value at vesting of the option awards that were granted to the reported named executive officers and vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.53pt">Represents the average aggregate change in fair value, measured from the prior fiscal year-end to the vesting date, of each option award held by the reported named executive officers that was granted in a prior fiscal year and which vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.46pt">Represents the average aggregate fair value as of the last day of the prior fiscal year of the reported named executive officers’ option awards that were granted in a prior fiscal year and which failed to meet the applicable vesting conditions in the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.</span></div> 2575012 2488366 2644678 2696607 2852428 -1770538 -1707982 -1870147 -1940015 -2154308 1479875 623274 1012372 4157531 7328264 -269292 -931629 -2233022 1099351 2776040 0 0 0 0 0 -158648 -676521 -779414 -1908971 1869973 0 0 0 0 -47077 1856409 -204492 -1225533 4104503 12625320 <span style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:6.44pt">The TSR Peer Group consists of the Nasdaq Biotechnology Index, an independently prepared index that includes companies in the biotechnology industry and which is the same industry index disclosed in our Annual Report on Form 10-K.</span> <div style="margin-bottom:9pt;margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#27596a;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Relationship Between Pay and Performance </span></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #27596a;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe the compensation actually paid in each of the years reported above and over the five-year cumulative period are reflective of the Compensation Committee’s emphasis on “pay-for-performance” as the compensation actually paid fluctuated year-over-year, primarily due to the result of our share performance and our varying levels of achievement against pre-established performance goals under our annual cash bonus opportunities and long-term incentive compensation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graphic illustrates the relationship between the compensation actually paid to the named executive officers and the Company’s TSR, as well as the relationship between the Company’s TSR and the TSR of the Nasdaq Biotechnology Index, an independently prepared index that includes companies in the biotechnology industry. In addition, as noted above, as is the case with many companies in the biotechnology industry, the Company’s annual incentive objectives are generally tied to the Company’s strategic and operational goals rather than financial goals. Accordingly, the Company’s compensation program is less influenced by metrics such as net income. In fiscal year 2021, our net income was </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$66,975,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as compared to the compensation actually paid of $41,144,072 to </span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dr. Kinney and $12,625,320 for the average of our other named executive officers. In fiscal year 2022, our net income decreased to $(116,949,000), while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $7,400,610 and $4,104,503, respectiv</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ely, primarily due to a smaller increase in our share price year-over-year. In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2023, our net income decreased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(147,028,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $(3,218,100) and $(1,225,533), respectiv</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ely, primarily due to a decrease in our share price year-over-year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2024, our net income increased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(122,310,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kinney and for the other named executive officers increased to $(1,707,034) and $(204,492), respectively, primarily due to a smaller decrease in our share price year-over-year. In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2025, our net income decreased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(244,092,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kinney and for the other named executive officers increased to $2,866,614 and $1,856,409, respectively, primarily due to a smaller decrease in our share price year-over-year.</span></div></div></div><img alt="10116" id="i-67" src="prta-20260327_g8.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:652px"/> <div style="margin-bottom:9pt;margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#27596a;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Relationship Between Pay and Performance </span></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #27596a;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe the compensation actually paid in each of the years reported above and over the five-year cumulative period are reflective of the Compensation Committee’s emphasis on “pay-for-performance” as the compensation actually paid fluctuated year-over-year, primarily due to the result of our share performance and our varying levels of achievement against pre-established performance goals under our annual cash bonus opportunities and long-term incentive compensation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graphic illustrates the relationship between the compensation actually paid to the named executive officers and the Company’s TSR, as well as the relationship between the Company’s TSR and the TSR of the Nasdaq Biotechnology Index, an independently prepared index that includes companies in the biotechnology industry. In addition, as noted above, as is the case with many companies in the biotechnology industry, the Company’s annual incentive objectives are generally tied to the Company’s strategic and operational goals rather than financial goals. Accordingly, the Company’s compensation program is less influenced by metrics such as net income. In fiscal year 2021, our net income was </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$66,975,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as compared to the compensation actually paid of $41,144,072 to </span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dr. Kinney and $12,625,320 for the average of our other named executive officers. In fiscal year 2022, our net income decreased to $(116,949,000), while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $7,400,610 and $4,104,503, respectiv</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ely, primarily due to a smaller increase in our share price year-over-year. In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2023, our net income decreased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(147,028,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $(3,218,100) and $(1,225,533), respectiv</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ely, primarily due to a decrease in our share price year-over-year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2024, our net income increased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(122,310,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kinney and for the other named executive officers increased to $(1,707,034) and $(204,492), respectively, primarily due to a smaller decrease in our share price year-over-year. In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2025, our net income decreased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(244,092,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kinney and for the other named executive officers increased to $2,866,614 and $1,856,409, respectively, primarily due to a smaller decrease in our share price year-over-year.</span></div></div></div><img alt="10116" id="i-67" src="prta-20260327_g8.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:652px"/> <div style="margin-bottom:9pt;margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#27596a;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Relationship Between Pay and Performance </span></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #27596a;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe the compensation actually paid in each of the years reported above and over the five-year cumulative period are reflective of the Compensation Committee’s emphasis on “pay-for-performance” as the compensation actually paid fluctuated year-over-year, primarily due to the result of our share performance and our varying levels of achievement against pre-established performance goals under our annual cash bonus opportunities and long-term incentive compensation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graphic illustrates the relationship between the compensation actually paid to the named executive officers and the Company’s TSR, as well as the relationship between the Company’s TSR and the TSR of the Nasdaq Biotechnology Index, an independently prepared index that includes companies in the biotechnology industry. In addition, as noted above, as is the case with many companies in the biotechnology industry, the Company’s annual incentive objectives are generally tied to the Company’s strategic and operational goals rather than financial goals. Accordingly, the Company’s compensation program is less influenced by metrics such as net income. In fiscal year 2021, our net income was </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$66,975,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as compared to the compensation actually paid of $41,144,072 to </span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dr. Kinney and $12,625,320 for the average of our other named executive officers. In fiscal year 2022, our net income decreased to $(116,949,000), while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $7,400,610 and $4,104,503, respectiv</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ely, primarily due to a smaller increase in our share price year-over-year. In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2023, our net income decreased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(147,028,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $(3,218,100) and $(1,225,533), respectiv</span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ely, primarily due to a decrease in our share price year-over-year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2024, our net income increased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(122,310,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kinney and for the other named executive officers increased to $(1,707,034) and $(204,492), respectively, primarily due to a smaller decrease in our share price year-over-year. In fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 2025, our net income decreased to </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(244,092,000)</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, while the compensation actually paid for Dr. </span><span style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kinney and for the other named executive officers increased to $2,866,614 and $1,856,409, respectively, primarily due to a smaller decrease in our share price year-over-year.</span></div></div></div> 66975000 41144072 12625320 -116949000 7400610 4104503 -147028000 -3218100 -1225533 -122310000 -1707034 -204492 -244092000 2866614 1856409 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#27596a;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Measures Used to Link Company Performance and Compensation Actually Paid to the Named Executive Officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #27596a;padding:0 1pt"></td></tr></table><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, as is the case with many companies in the biotechnology industry, the Company relies less on financial performance goals as compared to non-financial strategic and operational goals. Below is a list of performance measures, which in the Company’s assessment represent the most important performance measures used by the Company to link compensation actually paid to the named executive officers for fiscal year 2025. Please see the Compensation Discussion and Analysis for further information regarding how each of these measures is used in the Company’s executive compensation program.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="background-color:#ffffff;color:#27596a;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:4.1pt">Share Price</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="background-color:#ffffff;color:#27596a;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:4.1pt">Progress R&amp;D Portfolio to Achieve Primary 2025 Milestones</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">For birtamimab, For birtamimab, execute engagement plan to support enrollment and potential commercialization; effectively communicate topline results of Phase 3 AFFIRM-AL trial.</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">For PRX012, effectively communicate topline results of Phase 1 clinical trials; reach decision regarding additional development.</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">For PRX019, complete the Phase 1 clinical trial through a specified cohort.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#27596a;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:4.1pt">Meet Cash Burn Guidance Range and Optimize Shareholder Base</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">Meet publicly-disclosed cash burn guidance range.</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.81pt">Optimize shareholder base by: retaining four of top six institutional investors; galvanizing at least one institutional investor (existing or new) to take a </span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5% ownership stake; or galvanizing at least five institutional investors (existing or new) to take a </span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1% ownership stake.</span></div></div></div> Share Price Progress R&D Portfolio Meet Cash Burn Guidance Range and Optimize Shareholder Base <div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.245%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is the Compensation Committee’s (or, in the case of Dr. Kinney, the Board’s) general practice to approve ordinary course annual equity awards at its regularly scheduled meeting held in February of each year. Following approval by the Compensation Committee or Board, as applicable, all annual equity awards for the fiscal year are made at a fixed, future date specified at the time of approval of the award. As in prior years, the Committee approved annual equity awards to our named executive officers in February 2025 and the Committee (or, in the case of Dr. Kinney, the Board) had the opportunity to consider our expectations and projections for fiscal year 2025. In addition, while we generally grant broad-based equity awards at approximately the same time each year following our release of full-year financial results, we may choose to grant equity awards outside of the annual broad-based awards (e.g., as a new hire, retention, or promotion award). Pursuant to the terms of the 2018 LTIP and the 2020 EIIP, stock options may be granted only with an exercise price at or above the closing market price of an ordinary share on the date of grant. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not schedule its equity awards in anticipation of the release of material, non-public information (“MNPI”), nor does the Company time the release of MNPI based on equity award grant dates. </span></div></div><div style="display:inline-block;max-width:3.508%;min-width:2.508%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event MNPI becomes known to the Committee or the Board prior to granting an equity award, the Committee or Board will take the existence of such information into consideration and use its business judgement to determine whether to delay the grant of such equity award. Since 2023, it has been both the Committee’s and the Board’s practice not to grant stock option awards during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing MNPI and ending one business day after the filing or furnishing of such a report with the SEC, and no stock options were granted to any of our named executive officers during such period during fiscal year 2025.</span></div></div></div> It is the Compensation Committee’s (or, in the case of Dr. Kinney, the Board’s) general practice to approve ordinary course annual equity awards at its regularly scheduled meeting held in February of each year. Following approval by the Compensation Committee or Board, as applicable, all annual equity awards for the fiscal year are made at a fixed, future date specified at the time of approval of the award. As in prior years, the Committee approved annual equity awards to our named executive officers in February 2025 and the Committee (or, in the case of Dr. Kinney, the Board) had the opportunity to consider our expectations and projections for fiscal year 2025. In addition, while we generally grant broad-based equity awards at approximately the same time each year following our release of full-year financial results, we may choose to grant equity awards outside of the annual broad-based awards (e.g., as a new hire, retention, or promotion award). Pursuant to the terms of the 2018 LTIP and the 2020 EIIP, stock options may be granted only with an exercise price at or above the closing market price of an ordinary share on the date of grant. true <div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not schedule its equity awards in anticipation of the release of material, non-public information (“MNPI”), nor does the Company time the release of MNPI based on equity award grant dates. </span></div><div style="display:inline-block;vertical-align:top;width:48.247%"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event MNPI becomes known to the Committee or the Board prior to granting an equity award, the Committee or Board will take the existence of such information into consideration and use its business judgement to determine whether to delay the grant of such equity award. Since 2023, it has been both the Committee’s and the Board’s practice not to grant stock option awards during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing MNPI and ending one business day after the filing or furnishing of such a report with the SEC, and no stock options were granted to any of our named executive officers during such period during fiscal year 2025.</span></div></div> false true